Scandion Oncology (SCOL) | Spotlight

Home

Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen.

Quotes for Scandion Oncology

Right Now

+/-: -0.78
%: -6,62%
Latest: 11
High: 11.96
Low: 10.74
Volume: 46 854
Turnover (SEK): 527 017
Value (MSEK): 209,6

Board

CEO

Nils Brünner

Chairman Of The Board

Peter Høngaard

Board

Carl Borrebäck
Christian Vinding Thomsen
Jørgen Bardenfleth
Thomas Feldthus

News

2019-11-29 14:25:39 Chairman and Vice-Chairman of the Board in Scandion Oncology A/S buy Company shares
2019-11-29 08:00:00 Scandion Oncology receives final approval from the Danish Medicines Agency for start of clinical Phase II trial in patients with drug resistant metastatic colorectal cancer
2019-11-21 12:28:28 Scandion Oncology CEO Newsletter November 2019
2019-11-21 08:30:00 Interim Report 1 January 2019 - 30 September 2019
2019-10-14 15:02:20 Scandion Oncology A/S receives EU-patent for SCO-101

Show More

News agencies

2019-11-29 14:44:11 Finwire: Formand og næstformand i bestyrelsen i Scandion Oncology køber aktier fra CEO og CSO
2019-11-29 14:31:41 Finwire: Scandion Oncologys ordförande och vice ordförande köper aktier från vd och forskningschef
2019-11-29 08:34:00 Finwire: Scandion Oncology får klartecken att starta fas II-studie med SCO-101
2019-11-29 08:12:04 Finwire: Scandion Oncology får grønt lys fra Lægemiddelstyrelsen til at begynde fase II-studie
2019-11-21 13:35:22 Finwire: Scandion Oncology forventer at starte fase II-studie med SCO-101 næste måned

Show More

Analysis

2018-10-09 SvD Börsplus: Svår att motstå?

Videos

Key Numbers

*Compiled data from Millistream

Annual reports, prospectus etc.